Imdur Prolonged-Release Tablets

Imdur's once-daily release profile distinguishes it from rescue treatment

Imdur is a prolonged-release isosorbide mononitrate tablet designed to release the medicine gradually over an extended period. This supports a once-daily preventive routine. It is not interchangeable with a fast-acting glyceryl trinitrate spray or tablet used to relieve an angina attack that has already begun.

If you are comparing nitrate medicines before ordering, the first decision is therefore about purpose rather than brand alone. Imdur may fit a treatment plan that calls for regular prevention, while a fast-acting nitrate addresses a different need. Some people are prescribed both types for their separate roles, but one should not be substituted for the other without clinical advice.

What is Imdur and where does it fit in angina treatment?

Imdur contains isosorbide mononitrate, an oral nitrate vasodilator used to help prevent angina in adults. Angina occurs when the heart muscle does not receive enough oxygen for its workload. By relaxing blood vessels and reducing the demands placed on the heart, isosorbide mononitrate can make an episode less likely to occur.

The prolonged-release dosage form is central to the identity of this product. It provides the active ingredient through a tablet intended for regular oral use, rather than through a spray, patch, immediate-release tablet or medicine taken only when pain starts. Imdur should not be used as emergency treatment for sudden chest pain.

We offer Imdur prolonged-release tablets in 20 mg, 30 mg, 40 mg and 60 mg strengths. These options allow the supplied product to match different prescribed doses, but they do not mean that every strength is suitable for every person. Dose selection depends on the treatment plan, response and tolerability assessed by the prescriber.

Who might consider Imdur, and what affects the choice?

Imdur may be considered for an adult with diagnosed angina who needs regular preventive treatment. It is not suitable for choosing solely from symptoms, because chest pain has many possible causes and requires appropriate clinical assessment. A prescriber may consider the pattern of angina, other medicines and the person's blood pressure before deciding whether a long-acting nitrate is appropriate.

Practical factors to discuss include:

• whether a once-daily prolonged-release tablet fits the intended treatment schedule;
• whether another nitrate is already being used, including a fast-acting medicine for attacks;
• current medicines for blood pressure, heart disease or erectile dysfunction;
• previous dizziness, fainting, severe headaches or low blood pressure with nitrate treatment;
• pregnancy or breastfeeding, which require individual medical assessment;
• the exact strength and tablet formulation stated in the treatment plan; and
• whether the medicine is intended for a child, as this prolonged-release treatment is not recommended for children.

No single factor makes Imdur universally preferable to another angina medicine. The relevant question is whether its prolonged-release formulation and dosing pattern fit the person's clinical needs and existing regimen.

How does prolonged-release isosorbide mononitrate work?

Isosorbide mononitrate acts through nitric oxide signalling in blood-vessel smooth muscle. This causes blood vessels to relax. Its strongest effect is on veins, although arteries can also be affected. The resulting reduction in the volume and pressure against which the heart must work lowers the heart muscle's oxygen demand.

This mechanism helps explain both the intended effect and several familiar nitrate side effects. Blood-vessel widening can cause headache, flushing, dizziness or light-headedness, particularly when treatment starts or the dose changes. These effects do not establish whether the dose is right, so persistent or troublesome symptoms should be discussed with a clinician rather than managed by changing the dose independently.

Long-term nitrate schedules also take account of tolerance, in which uninterrupted nitrate exposure can reduce the medicine's effect. The prescribed dose and timing should therefore be followed consistently rather than moved around to suit individual symptoms.

A consistent daily routine supports preventive treatment

Imdur is taken regularly to help prevent angina; it is not taken only when symptoms appear. The instructions on the dispensing label and patient information leaflet should take priority, but the following habits can support safe use:

1. Take the dose at the same time each day unless the prescriber gives different instructions.
2. Swallow the tablet with water. Do not crush or chew a prolonged-release tablet.
3. Only divide a tablet if the leaflet for the exact supplied strength states that it may be divided or a clinician has specifically instructed you to do so.
4. Do not take an extra dose to compensate for a forgotten tablet without checking the leaflet or obtaining professional advice.
5. Continue the prescribed routine even when angina is well controlled, because the medicine is being used preventively.
6. Do not stop long-term nitrate treatment suddenly unless a clinician advises it.

Store the tablets at 25°C; permitted temperature excursions are from 15°C to 30°C. Keep them in their supplied packaging and follow any additional storage directions on the label or leaflet.

If chest pain occurs, follow the action plan provided by the prescriber, including instructions for any fast-acting nitrate. New, severe or persistent chest pain can require urgent medical help and should not be managed by taking extra Imdur.

Matching the strength and pack quantity

Our Imdur range includes 20 mg, 30 mg, 40 mg and 60 mg prolonged-release tablets. Available pack quantities run from 30 to 360 tablets, although the exact quantities differ by strength. A visible pack option should therefore be checked against both the required strength and the intended treatment period.

A larger pack can reduce the frequency of repeat orders for someone established on a stable treatment plan, while a smaller available pack may be more appropriate when the regimen is being reviewed. Pack convenience should not drive dose selection. A higher-strength prolonged-release tablet should not be used to approximate a lower dose unless division is expressly permitted for that exact tablet and a clinician has given matching instructions.

Before ordering, compare the product name, strength, dosage form and quantity with the details you have been given. Our pharmacist-supported team can help clarify the catalogue options, but changes to the prescribed dose or medicine require advice from the treating clinician.

Expected benefits and timing

Imdur is intended to reduce the frequency or severity of angina episodes during regular use. It does not guarantee complete freedom from symptoms, and its value is assessed from the pattern of angina over time rather than from rapid relief after a single tablet.

This makes the expected outcome different from that of a short-acting nitrate. Glyceryl trinitrate used for an attack is selected for rapid action, whereas Imdur is selected for sustained preventive treatment. If attacks become more frequent, occur with less exertion, wake you at night or no longer respond as expected to the emergency plan, clinical review is important.

Headache is a common effect when nitrate treatment begins and may become less troublesome as the body adjusts. Dizziness, flushing, weakness or light-headedness can also occur. A severe reaction, fainting or symptoms that interfere with daily activities warrant prompt professional advice.

Important safety priorities before use

Imdur must not be used by anyone with a known allergy to isosorbide mononitrate, another nitrate or an ingredient in the supplied tablet. It can lower blood pressure, so a history of very low blood pressure, fainting or medicines with similar effects needs to be reviewed before treatment.

UK product information advises that isosorbide mononitrate prolonged-release tablets should not be used during pregnancy unless the prescriber considers treatment essential. It is not known whether isosorbide mononitrate passes into human milk, so a clinician must assess the benefits and risks before use while breastfeeding. The prolonged-release tablets are not recommended for children because an appropriate paediatric dose has not been established.

Dizziness, headache, blurred vision or reduced alertness may occur, especially at the start of treatment, after a dose change or with alcohol. Do not drive or operate machinery if affected.

Review the following product-specific points before starting or reordering:

If the checklist identifies a concern, discuss it with a prescriber or pharmacist before taking the medicine. It is particularly important not to conceal use of erectile-dysfunction treatment or another medicine that substantially lowers blood pressure.

Interactions and day-to-day precautions

The most important interactions arise when another medicine amplifies the blood-pressure-lowering effect of a nitrate. A complete medicines review should include prescribed products, non-prescription medicines and recreational substances.

• PDE5 inhibitors: sildenafil, tadalafil and vardenafil must not be combined with nitrates because the combination can cause a severe and potentially dangerous fall in blood pressure.
• Riociguat: this medicine also acts on the nitric oxide pathway and should not be combined with nitrate treatment.
• Blood pressure and heart medicines: beta-blockers, calcium-channel blockers and other medicines that lower blood pressure may increase dizziness or hypotension. They are sometimes deliberately used together, but the regimen requires clinical oversight.
• Alcohol: alcohol can intensify dizziness and the fall in blood pressure, particularly when treatment begins or the dose changes.
• Postural symptoms: standing up quickly can cause light-headedness. Rising slowly and taking care after sitting or lying down can reduce the chance of a fall.

This is not a complete interaction list. A pharmacist or prescriber should check the full regimen, especially before another medicine is started, stopped or adjusted.

Imdur compared with other angina medicines

The alternatives differ in speed, duration and mechanism. The best fit depends on the purpose of treatment, other health conditions and side-effect profile rather than on one option being universally stronger or better.

Monoket and Ismo are other names associated with isosorbide mononitrate, but brand name alone does not establish the release type, dose or dosing frequency of a specific product. The exact formulation must be checked before any comparison or switch.

These related medicines are not sold in our catalogue and are included only to explain the available treatment categories. Readers comparing broader options can view our heart disease medicines and blood pressure medicines ranges. A medicine from another class should only replace Imdur when that change has been clinically agreed.

UK prescription status and access

Isosorbide mononitrate is a prescription-only medicine in the United Kingdom. That legal classification is separate from our checkout process and remains relevant when considering whether the medicine has been appropriately prescribed and supplied.

Our current ordering policy does not require customers to submit a prescription during checkout. This commercial process does not change Imdur's UK classification or replace an appropriate clinical assessment. The NHS provides patient information about taking isosorbide mononitrate, side effects and important precautions, while NICE guidance explains the role of anti-anginal treatment in stable angina care. Suspected side effects can be reported to the MHRA through the Yellow Card scheme.

Ordering and support

MedicalBrandNames has operated since 2017. We show the available Imdur strengths and pack quantities in our catalogue, with prices displayed in pounds sterling. Before ordering, check that the selected option matches the required product name, prolonged-release dosage form, strength and quantity.

Our support team is available 24/7 by email, online chat and phone. A pharmacist is available to answer medicine-related questions and help distinguish a catalogue query from an issue that needs referral to the prescriber. Support can also clarify the ordering information presented during checkout. We do not assume delivery times, destination requirements or other fulfilment details that are not shown for the individual order.

The final decision should match the treatment plan

Imdur is a practical option when the intended treatment is once-daily, prolonged-release isosorbide mononitrate for the prevention of angina. Its main distinction is not that it is universally better than another nitrate, but that its dosage form and routine serve a specific preventive role.

Before ordering, confirm four details: the Imdur name, the prolonged-release tablet form, the prescribed strength and the required pack quantity. If the treatment plan instead specifies a fast-acting nitrate, another release type or a medicine from a different drug class, that difference should be resolved before purchase. When all four details match, the remaining decision is which available pack quantity appropriately supports the agreed routine.